Carbon in the 2-position of leucine undergoes several additional metabolic steps before entering the tricarboxylic acid (TCA) cycle in the 1-position of acetyl-CoA, where it can be released as CO2 or be incorporated into other compounds. This study examined the metabolic fate of C in the 2-position of leucine. We infused 11 healthy subjects with [1-
C in blood and expired CO2. The fraction of leucine infused that was oxidized (fox) was used to define the degree of recovery of the 13 C label(s) for each tracer. As expected, leucine appearance (means Ϯ SE) did not differ between tracers ( 13 C1: 92.1 Ϯ 3.1 vs.
13 C2: 89.2 Ϯ 3.2 mol ⅐ kg Ϫ1 ⅐ h Ϫ1 ) when calculated using plasma leucine enrichments as an index of intracellular enrichment. A small (3%) but significant (P ϭ 0.048) difference between tracers was found when KIC was used to calculate leucine appearance ( 13 C1: 118.0 Ϯ 4.1 vs. 13 C2: 114.4 Ϯ 4.5 mol ⅐ kg Ϫ1 ⅐ h Ϫ1 ). The value of fox was 14 Ϯ 1% for [1,2- 13 C2]leucine and was lower than the fox for [1- 13 C]leucine (19 Ϯ 1%) . From the fox data, we calculated that the recovery of the 2- 13 C label in breath CO2 was 58 Ϯ 6% relative to the 1- 13 C label. These findings show that, although a majority of the 2- 13 C label of leucine is recovered in breath CO2, a significant percentage (ϳ42%) is retained in the body, presumably by transfer to other compounds, via TCA exchange reactions. leucine oxidation; leucine kinetics ISOTOPE TRACERS labeled with 13 C or 14 C have been used to assess the oxidation of a variety of metabolic substrates. At isotopic steady state, measurements of the enrichment or specific activity of the carbon (C) label in expired CO 2 and the precursor pool for oxidation (usually plasma) permit the calculation of both the turnover and oxidation rates of the given substrate. For example, the essential amino acid leucine, labeled with 13 C or 14 C in the carboxyl position (e.g., [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]leucine), can be used to measure leucine turnover and oxidation (11) . The isotope label in the carboxyl position is released as CO 2 when leucine is irreversibly committed to oxidation with the decarboxylation of ␣-ketoisocaproate (KIC; see Fig. 1 ) (8) . Thus the appearance of the 13 C label in breath CO 2 provides a direct measure of leucine oxidation.
Unlike a carboxyl-labeled leucine that is released directly as CO 2 , a C label placed in many substrates is not released as CO 2 until after it has passed through the tricarboxylic acid (TCA) cycle. Passage of the tracer through the TCA cycle creates a potential problem in the interpretation of oxidation data, because some of the C label may be incorporated into other compounds (e.g., glucose, glutamine/glutamate) via TCA cycle exchange reactions instead of being released as CO 2 (15) . Oxidation of a C-labeled substrate will be underestimated from breath CO 2 measurements according to the degree of label retention during passage through the TCA cycle.
This problem of retention of C label has been evaluated using tracers of metabolites that enter directly into the TCA cycle. For example, acetate enters directly into the TCA cycle as acetyl-CoA, and studies using labeled acetate have been performed to define the degree of label retention in TCA cycle intermediates in dogs and in humans (2) . These studies showed that a substantial portion (ϳ30%) of the 13 C label of acetate was retained in the body, presumably through transfer into other compounds via TCA exchange reactions. Data from infusions of labeled acetate have been proposed to be used to correct oxidation data from substrates that have small intracellular pools and are metabolized directly to acetyl-CoA, such as fatty acids (19) . In such substrates, the probability that the C label will be lost before entry into the TCA cycle is minimal.
Another limitation of all tracer oxidation studies is that the C label must pass through the body bicarbonate pool, where the C label can be retained through pathways not leading to release as exhaled CO 2 . Bicarbonate kinetics and retention of C have been examined in a variety of studies (1, 3) . These studies have shown both constancy and variability of bicarbonate retention. None of the studies infusing labeled acetate and measuring acetate label recovery in exhaled CO 2 has simultaneously measured bicarbonate C retention with a labeled bicarbonate infusion. Thus the acetate C-label retention values include retention of C from both the TCA cycle and the bicarbonate pool.
In performing studies with the use of both L-[1-
13
C]leucine and L-[1,2-13 C 2 ]leucine, we realized that we had two tracers with the potential to define retention of C metabolized to acetyl-CoA while simultaneously correcting for many of the other limitations mentioned above. Infusion of [1- 13 C]leucine results in direct decarboxylation of the 13 C to produce "metabolically-derived" CO 2 , which then passes through the bicarbonate pool. The same is true of the carboxyl 13 C of [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]leucine; however, the second 13 C of this tracer will undergo several metabolic steps and then become [1- 13 C]acetyl-CoA. Thus, by measuring the differential recovery of 13 Before each infusion study, sterile solutions of the administered isotopes were prepared using aseptic techniques. Compounds were accurately weighed and dissolved in weighed volumes of sterile, pyrogen-free, 0.45% saline and filtered through a 0.22-m sterile filter before use. An aliquot of the sterile solution was initially verified to be pyrogen free before administration. Solutions were prepared Յ48 h before use and were kept at 4°C until use.
Subjects. Eleven healthy male (n ϭ 8) and female (n ϭ 3) adult volunteers having normal weights for heights [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] yr old (mean Ϯ SD ϭ 26 Ϯ 5 yr) and 49-114 kg (mean Ϯ SD ϭ 74 Ϯ 18 kg)] were studied at the University of Vermont General Clinical Research Center (CRC). Before study, a medical history was obtained, and physical examinations and biochemical laboratory tests were performed to verify that subjects were healthy and free of disease. Volunteers were informed of the purpose and risks of the study before giving consent to participate. The experimental protocol was approved by the Committee on Human Research for the Medical Sciences of the University of Vermont.
Experimental protocol. Each subject participated in two infusion studies of either protocol 1 or protocol 2, outlined in Infusion protocols. For both protocols, each subject was admitted to the CRC on the day before each infusion study. Subjects were asked to consume a weight-maintaining, liquid diet (Ensure Plus, Ross Laboratories, Columbus, OH) of adequate and known caloric and protein content that day. The last meal was consumed before 1900, and subjects drank only water until the completion of the infusion study on the following day. After an overnight stay at the CRC, subjects were awakened at 0600 and allowed to void. Catheters were placed in an antecubital vein for infusion (18 gauge) and retrogradely in a dorsal hand vein of the contralateral arm (20 gauge) for blood sampling. The hand was placed in a warming box (air temperature 55°C) to obtain arterialized venous blood. The catheters were kept patent with infusions of 0.45% saline (30 ml/h).
Infusion protocols. Two separate but related protocols were conducted (Fig. 2) . Seven subjects (all men) participated in protocol 1. In protocol 1, a primed, continuous infusion of either [1- 13 C]leucine or [1,2-13 C2]leucine was started at 0700 and continued for 3.5 h. At that point, the tracer infusion was 13 C]leucine infusion. Blood and breath samples were obtained before the start of tracer administration, at 15-min intervals during the last 1.5 h of the 4-h tracer infusion, at 15-min intervals for the hour after discontinuation of the infusion, and at 30-min intervals for the next 2 h after discontinuation of the tracer infusion. Each subject completed two infusion studies two days apart, where [1-
13 C]leucine was infused on the first day and [1,2-
13 C2]leucine was infused on the second (order randomized among subjects).
In every infusion study, oxygen consumption and carbon dioxide production were determined by indirect calorimetry with the use of a ventilated hood technique (DeltaTrac, Sensor Medics, Yorba Linda, CA) for 15-min intervals five or six times throughout each infusion period. Breath samples were placed into 20-ml evacuated tubes until later analysis for 13 CO2 enrichment by isotope ratio mass spectrometry (IRMS). The 13 C enrichment [atom % excess (ape)] of expired CO2 in the breath samples was measured by IRMS (VG SIRA II, Middlewich, Cheshire, UK). Blood samples were placed in heparinized tubes and stored on ice until the plasma was separated by centrifugation (4°C) and frozen at Ϫ70°C until later analysis.
Analytical methods. Plasma leucine concentrations and enrichments were measured by negative chemical ionization GC-MS, and KIC plasma concentrations and enrichments were measured by electron impact ionization GC-MS, both as previously described (9) . In brief, samples were prepared by adding accurate aliquots of ]KIC, respectively. For each sample, the area under the leucine and KIC peaks for the each ion monitored was determined by the GC-MS data system, and these areas were used to form ion intensity ratios, either as the labeled masses against the unlabeled for measuring tracer enrichments or as unlabeled against the mass from the 2 H peak area for measuring amino and keto acid concentrations. The tracer-to-tracee mole ratios (TTR) for the 13 C2 and 13 C1 species of leucine and KIC were determined from the ion intensity ratios as previously described (4) . Standards of known [1,2- 13 C2]-and [1-
C]-leucine and [1,2- 13 C2]-and [1-13 C]KIC tracer-to-tracee content were run along with all samples. These standards were used to calibrate each day's GC-MS measurements of samples when the GC-MS ion intensity ratio data were transformed into TTRs. The TTR values were then converted as required to tracer enrichments as mole fractional excess of tracer: E ϭ 100 ⅐ [TTR/(1ϩTTR)], where E is expressed as mole percent excess (mpe) of the specific tracer species.
Kinetic calculations. The rate of appearance (R a) of leucine in plasma was calculated from tracer enrichments at plateau for [1- 13 C]leucine and [1,2-13 C2]leucine as
where x ϭ 1 for [1- ]leucine, i x is the molar rate of the respective leucine tracer (mol of tracer ⅐ kg Ϫ1 ⅐ h Ϫ1 ), and Ex is the mean plasma enrichment (mpe) of the respective leucine tracer in plasma at isotopic steady state. The factor 100 normalizes the enrichment in percentages. Leucine Ra was calculated using plasma leucine tracer enrichments (hereafter referred to as the primary pool model) and using plasma KIC tracer enrichments (hereafter referred to as the reciprocal pool model) as proxy measures of intracellular leucine enrichment (12). The rate of 13 CO2 excretion into expired air (F13C; mol
where FCO2 is the CO2 production rate (mmol ⅐ kg Ϫ1 ⅐ h Ϫ1 ), ECO2 is the enrichment of expired 13 CO2 (ape 13 C), the constant factor 10 accounts for unit changes, and the factor 0.81 accounts for the recovery in exhaled air of 13 CO2 released into the body bicarbonate pool (1) .
Division of F13C by the rate of tracer 13 C (i13C2) because two C atoms are labeled with 13 C. Thus the tracer infusion rate in Eq. 3 must reflect the rate of 13 C-atom tracer infusion, whereas the infusion rate in Eq. 1 reflects the leucine tracer-molar infusion rate.
Our primary goal was to define the recovery of the 13 C label in the 2-position of leucine in breath 13 CO2. The fraction of infused [1- 13 C]leucine oxidized to 13 CO2 (fox1) defines the extent of oxidation of the 1-C of leucine. The fraction of infused [1,2- 13 C2]leucine tracer oxidized to 13 CO2 is sum of the oxidation of the 1-C and the 2-C. Thus, for a given infusion study, the fraction of the infused 2-C oxidized to CO2 relative to the 1-C (F2/1) will be
With the assumption that the 1-C of leucine is released 100% into the CO2/bicarbonate pool, F2/1 expresses the fraction of the 2-C that is released as CO2 relative to the 1-C. Note that any uncertainty from use of a fixed value for recovery of 13 C label in exhaled CO2 in Eq. 2 cancels from Eq 4, making the determination of F2/1 independent of bicarbonate kinetics.
The purpose of this study was to test our ability to measure recovery in humans of metabolic C entering as the carboxyl-C of acetyl-CoA by use of infusions of L- [1- 13 C]leucine and 
RESULTS
Leucine and KIC concentration and enrichment data and leucine R a for protocol 1 are shown in Table 1 . A time effect (P Ͻ 0.05) was found for plasma leucine concentrations, indicating that the plasma leucine concentration increased as the duration of the fasting period increased. No effect of time or tracer was found for KIC concentrations. There was no difference in either leucine or KIC concentrations between studies, and concentration values were typical for an overnight fast. Because the [1- No differences were found with time or between tracers for R a leucine calculated using the primary pool model. In contrast, a small tracer effect was found (P ϭ 0.048) for CO 2 relative to the 1-13 C label. When f ox values were used from the same study day, there was a significant (P Ͻ 0.001) difference in 2-13 C recovery between studies 1 and 2 (74 vs. 41%), indicating that the order of tracer infusion produced differences in 13 CO 2 recovery. These results show a carryover of the 13 C label from the first 3.5-h infusion into the second 3.5-h infusion. When 2-13 C recovery was calculated using 13 CO 2 data across infusion days for a specific infusion period (i.e., first vs. second 3.5 h), the recovery of 2-13 C tracer was not significantly different (56 vs. 59%).
The conclusion from protocol 1 is that the order of tracer infusion ([ ]leucine tracer infusions had been stopped. Our intent in protocol 2 was to define the effect of 13 C tracer carryover on the recovery of the 13 C label(s) in expired 13 CO 2 . The plateau enrichments and time course for the decay in enrichments after cessation of the infusions are shown in Fig. 3 for protocol 2. The average plateau enrichments and concentrations for leucine and KIC for protocol 2 are shown in Table 3 . In protocol 1, the leucine tracer infusion rates were set to produce similar enrichments of 13 CO 2 between the [1-13 C]-and [1,2-
13
C 2 ]leucine infusions. In protocol 2, the infusion rates of the tracers were set equal to keep the plasma tracer molar enrichments the same (Fig. 3) . Thus no differences were found between studies for plasma leucine or KIC concentration or for tracer enrichments at isotopic steady state (samples taken between hours 3 and 4; Fig. 3 and Table 3 ). Similarly, the R a leucine (calculated by use of both the primary and the reciprocal pool models from the tracer data from infusion hours 3-4) did not differ between studies.
The CO 2 production rates, breath 13 CO 2 enrichments, and excretion rate data taken at plateau (hours 3.25-4) for protocol 2 are shown in Table 4 . There was no difference in CO 2 production between studies. As expected, the breath 13 CO 2 enrichment and excretion rates were greater in study 2 when [1,2- (Table 4) . We also measured plasma leucine d P Ͻ 0.001 difference between tracers. Recovery of the 2-13 C label was calculated using Eq. 4 in two ways: 1) using 13 CO2 data for the first and second halves from the same infusion day for each subject (within studies) and 2) using 13 CO2 data for each subject across infusion days for the same infusion periods (between studies).
e P Ͻ 0.001 difference between values by paired t-test.
[1-
C]leucine infusion, indicating that the 2-
C passed through an additional pool prior to recovery as 13 CO 2 . The decay constants from Table 5 were then used to estimate the time course of the decay in [1- 13 C]-and [1,2-13 C 2 ]leucine enrichments during the second 3.5 h of each infusion in protocol 1. Because the leucine and KIC enrichments are measured as discrete isotopomers in plasma, there is no interference of one tracer into the other's plasma enrichment measurement. However, that is not the case for breath 13 CO 2 . From the kinetic fit data in Table 5 , we estimate that the 13 C 1 leucine tracer carryover from period 1 would account for ϳ10% of the breath 13 CO 2 at the end of the second-half [1,2-13 C 2 ]leucine infusion in protocol 1. Conversely, the 13 C 2 leucine tracer carryover from period 1 into the second half would account for ϳ20% of the breath 13 CO 2 at the end of the second-half [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]leucine infusion. Thus we can use the protocol 2 fitted data of Table 5 to correct the 13 CO 2 enrichment data obtained in protocol 1 during the second-half infusion for tracer carryover from the first half.
The corrected second 3.5-h infusion period data for 13 CO 2 excretion and the fraction of tracer oxidized to 13 CO 2 were then used to calculate corrected 2-13 C label recovery values for protocol 1. These data are shown in Table 6 . There were still significant differences for 13 CO 2 excretion and the fraction of tracer oxidized to CO 2 between tracer types. However, there were no longer significant differences in 13 CO 2 excretion with time (i.e., first vs. second half). The recovery of the 2-13 C relative to the 1-
C also no longer showed significant differences when calculated within each study between the first and second infusion periods. The mean "within study" recovery was (49 ϩ 54)/2 ϭ 51%, and the mean difference in recovery between studies was (56 ϩ 48)/2 ϭ 52%.
Finally, we combined the between-study values of 2-13 C recovery of protocol 1, where seven subjects were studied, and 2-13 C recovery values of protocol 2, where four subjects were studied. By use of these data (n ϭ 11), the mean recovery for the 2-13 C label was 58 Ϯ 6%.
DISCUSSION
The goal of this study was to use two tracers of leucine to probe the lower reaches of intermediary Data are means Ϯ SE for 4 subjects. Plasma enrichments are the mean enrichments taken for each subject at plateau (3.25-4 h). No significant differences were found between studies in any variable shown. Data are means Ϯ SE for 4 subjects. * P Ͻ 0.01 difference between studies by paired t-test. . Solid lines represent the best fit of the data to the exponential decay equations shown in Table 5. metabolism. Specifically, the recovery of the 2-13 C label of [1,2-13 C 2 ]leucine in expired CO 2 was compared with the recovery of [1-
13 C]leucine in expired CO 2 . The recovery of the 1-13 C label was used to define retention of tracer once it had entered the metabolic CO 2 pool. In contrast to the 1-13 C label, the 2-13 C of leucine is not released as 13 CO 2 until it has been reduced to acetylCoA (Fig. 1) . Using this method, we found that 58 Ϯ 6% of the 2-13 C label was recovered in breath CO 2 relative to the 1-
13
C label of leucine. Another point of this study was that the movement of the [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]leucine and the [1,2-13 C 2 ]leucine tracers from KIC to exhaled CO 2 was kinetically different between the two tracers. That is, the rate of tracer clearance up to and through the bicarbonate pool was slower when the [1,2-13 C 2 ]leucine tracer was administered than it was when the [1-
13 C]leucine was infused (Table 5) . This difference is due to a separate pool after the conversion of the [1,2-13 C 2 ]leucine label to [1-13 C]-isovaleryl-CoA and before entry of the 13 C into the bicarbonate pool.
The equivalence of the metabolism of the two tracers can be established up through decarboxylation of KIC by comparing the kinetics of leucine and KIC 13 C disappearance from plasma after cessation of infusion in protocol 2. The disappearance of both leucine and KIC enrichments from plasma was similar between the [1-
13 C]-and [1,2-
C 2 ]leucine tracers (Table 5) , indicating identical kinetics up to and through KIC. Moreover, the measured leucine R a values were the same for the [1- 13 C]-and [1,2- Data are means Ϯ SE for 4 patients, each studied twice. The disappearance of enrichment after discontinuation of the tracer infusion was fitted to a 1-pool (At ϭ A1 ⅐ e
Ϫk1t
) and a 2-pool (At ϭ A1 ⅐ e Ϫk1t ϩ A2 ⅐ e Ϫk2t ) exponential model. Best significant fits were determined to be 2 pools for leucine and KIC and 2 pools for CO2. Time (t) was defined to start (t ϭ 0) at 4 h after discontinuation of the infusion. CO2 excretion data in the 2nd half of each infusion were corrected for carryover of 13 C from the tracer infused in the 1st half by use of the kinetic data obtained in Table 5 . The recovery of the 2-13 C label was calculated from the corrected fox data in this table, as described in Table 2 legend and Eq. 4. Repeated-measures ANOVA testing of the F13C and fox data were as described in Table 2 . * P Ͻ 0.01, significant effect between infusions of the [1- C label was calculated using Eq. 4 as in Table 2 in 2 ways: 1) using 13 CO2 data for the 1st and 2nd halves from the same infusion day for each subject (within studies) and 2) using 13 CO2 data for each subject across infusion days for the same infusion periods (between studies). No significant differences were found between values by paired t-test. from the bicarbonate pool. We should have anticipated that this result might occur and would affect a study designed to infuse one tracer after the other. However, protocol 1, with back-to-back infusions, was performed before protocol 2 because we had assumed that the kinetics of bicarbonate metabolism would dampen the effect of earlier pools on exhaled 13 CO 2 . Administering both tracers on the same day also removes day-to-day variability in metabolism. Although protocol 2 demonstrated differences in release of 13 C label between the two leucine tracers even after 3 h, the results of protocol 2 could be used to correct the influence of the firsthalf tracer infusion on the second half in protocol 1 and remove the tracer effect upon that study.
The 2- (15, 16, 19) . The duration of the infusions and the metabolic state of the volunteers (postabsorptive) were identical to those in the present study. However, the retention of 13 C label reported in these studies includes retention through the bicarbonate system. The carboxyl-labeled acetate recovery was not separated from bicarbonate label retention. In contrast, our use of a pair of leucine 13 C tracers determines the recovery of the second C separately from bicarbonate retention of label. To compare our results to the literature data with the use of acetate tracer infusions, we must first correct reported values for bicarbonate retention of label.
Applying an assumed 78% bicarbonate correction factor, Pouteau et al. (16) 13 CO 2 for a 3-h infusion of acetate tracer. If we correct this value for an assumed bicarbonate recovery of 81%, the oxidation of the 1-C of acetate becomes 56 Ϯ 3% in this second study. These three studies highlight the range of reported results. Our value of 58 Ϯ 6% recovery of the 2-13 C label of leucine is less than, but similar to, other reported values using acetate tracers.
Are our estimates of retention of C from acetyl-CoA by use of a pair of leucine tracers superior to the use of an acetate tracer coupled with a bicarbonate tracer? First, the measurements that we report would be simpler to interpret if we had used a [2- C]leucine tracer. Second, use of a pair of leucine tracers does have the advantage of measuring retention of label through the acetate pool while simultaneously determining bicarbonate C-label retention, but bicarbonate label retention could also be determined using an acetate-bicarbonate tracer combination. Third, there may be differences in the metabolism of leucine compared with acetate.
An infused acetate tracer enters the cell and likely enters directly into the mitochondria for oxidation. The degree of label oxidation in the TCA cycle derived from infusions of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate should be a maximal estimate. In contrast, the leucine tracer forms [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetyl-CoA from [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]isovaleryl-CoA within the mitochondria after several intermediate reactions (Fig. 1) . The possibility exists for some label retention during these metabolic steps. For example, in the liver and possibly other tissues, ␣-ketoisocaproate can be converted to ␤-hydroxy-␤-methylbutyrate, which can then be excreted in the urine or metabolized to mevalonate and be used for cholesterol synthesis. However, only a relatively small amount of leucine oxidation is thought to proceed through this pathway (14) .
There may also be organ-specific differences in metabolism between leucine and acetate tracers. The majority of whole body leucine oxidation takes place in nonsplanchnic tissues such as skeletal muscle (10), whereas a larger proportion of infused acetate is metabolized by splanchnic tissues (2) . Although Mittendorfer et al. (13) showed that recovery of [1- 13 C]acetate was similar in the postabsorptive state between splanchnic and leg tissues, there may be some tissuespecific differences in the metabolism of leucine and acetate. If anything, the use of the leucine tracers focuses on muscle metabolism of the tracer.
In conclusion, we present data from a pair of leucine tracers that can be used to evaluate intermediary metabolism. We found that 58 Ϯ 6% of the 2-13 C label of [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]leucine was recovered in breath CO 2 relative to the 1-13 C label. This value represents the intracellular fate of acetyl-CoA and represents that fraction of acetyl-CoA that enters the TCA cycle and is oxidized. This approach provides an alternative to infusion of labeled acetate and will simultaneously provide measurement of protein kinetics via leucine.
